Angiotensin II as a renal growth factor

Contributions to Nephrology

Volumn 135, Issue , 2001, Pages 92-110

  Wolf, Gunter ^a,b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; GROWTH PROMOTOR;

ANIMAL; CHRONIC KIDNEY FAILURE; HUMAN; KIDNEY; PHYSIOLOGY; PROGNOSIS; REGENERATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SENSITIVITY AND SPECIFICITY;

ANGIOTENSIN II; ANIMALS; GROWTH SUBSTANCES; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PROGNOSIS; REGENERATION; RENIN-ANGIOTENSIN SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 0035538359     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000060159     Document Type: Article

References (135)

1. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 1988;318:1657-1666.
2. Addis T, Oliver J: The Renal Lesion in Bright's Disease. New York, Hoeber, 1931.
3. Hostetter TH, Olson JL, Rennke HG, Venkatachlam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F93.
4. Brenner BM: Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249:F324-F337.
5. Yoshida Y, Fogo A, Ichikawa I: Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 1989;35:654-660.
6. Hostetter TH: Progression of renal disease and renal hypertrophy. Annu Rev Physiol 1995;57:263-278.
7. Zatz R: Haemodynamically mediated glomerular injury: The end of a 15-year-old controversy? Curr Opin Nephrol Hypertens 1996;5:468-475.
8. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P, Endlich K: Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 2001;12:413-422.
9. Daniels DS, Hostetter TH: Adverse effects of growth in the glomerular microcirculation. Am J Physiol 1990;258:F1409-F1416.
10. Miskell CA, Simpson DP: Hyperplasia precedes increased glomerular filtration rate in rat remnant kidney. Kidney Int 1990;37:758-766.
11. Wolf G, Neilson EG: Molecular mechanisms of tubulointerstitial hypertrophy and hyperplasia. Kidney Int 1991;39:401-420.
12. Schuster VL, Kokko JP, Jacobson HR: Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules. J Clin Invest 1984;73:507-515.
13. Anderson S, Rennke HG, Brenner BW: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
14. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I: Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991;40:195-202.
15. Gilbert RE, Wu LL, Kelly DJ, Cox A, Wilkinson-Berka JL, Johnston CI, Cooper ME: Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Am J Pathol 1999;155:429-440.
16. Wolf G: Molecular mechanisms of angiotensin II in the kidney: Emerging role in the progression of renal disease: Beyond haemodynamics. Nephrol Dial Transplant 1998;13:1131-1142.
17. Harris RC, Martinez-Maldonado M: Angiotensin II-mediated renal injury. Miner Eletrolyte Metab 1995;21:328-335.
18. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insuffciency. N Engl J Med 1996;334:939-945.
19. The GISEN group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtratiuon rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863.
20. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE: Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000;35:695-707.
21. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, Salvadori M, Remuzzi G: In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. J Am Soc Nephrol 1999;10:997-1006.
22. Fogo AB: Progression and potential regression of glomerulosclerosis. Kidney Int 2001;59:804-819.
23. Suzuki Y, Ruiz-Ortega M, Egido J: Angiotensin II: a double-edged sword in inflammation. J Nephrol 2001;13(suppl 3):S101-S110.
24. Ichikawa I, Harris RC:Angiotensin actions in the kidney: Renewed insight into the old hormone. Kidney Int 1991;40:583-596.
25. Wolf G: Vasoactive substances as regulators of renal growth. Exp Nephrol 1993;1:141-151.
26. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993;3:1531-1540.
27. Wolf G, Neilson EG: Angiotensin II as a hypertrophogenic cytokine for proximal tubular cells. Kindey Int 1993;43(suppl 39):S100-S107.
28. Shankland SJ, Wolf G: Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation, and apoptosis. Am J Physiol Renal Physiol 2000;278:F515-F529.
29. Wolf G: Cellular mechanisms of tubule hypertrophy and hyperplasia in renal injury. Miner Electrolyte Metab 1995;21:303-316.
30. Nasmyth K: Viewpoint: Putting the cell cycle in order. Science 1996;274:1643-1645.
31. Grana X, Reddy EP: Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-219.
32. Morgan DO: Principles of CDK regulation. Nature 1995;374:131-134.
33. Draetta G, Beach D: Activation of cdc2 protein kinase during mitosis in human cells: Cell cycle-dependent phosphorylation and subunit rearrangement. Cell 1988;54:17-26.
34. cdc2: In vivo veritas? Cell 1990;61:549-551.
35. 1 cyclins. Cell 1993;73:1059-1065.
36. Buchkovich K, Duffy LA, Harlow E: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 1989;58:1097-1105.
37. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
38. Harbour JW, Dean DC: The Rb/E2F pathway: Expanding roles and emerging paradigms. Gene Dev 2000;14:2393-2409.
39. Peter M, Herskowitz I: Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994;79:181-184.
40. 1 cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000;12:676-684.
41. Shankland SJ: Cell-cycle control and renal disease. Kidney Int 1997;52:294-308.
42. Hengst L, Reed SI: Inhibitors of the Cip/Kip family. Curr Top Microbiol Immunol 1998;227:25-41.
43. 1-phase progression. Gene Dev 1999;13:1501-1512.
44. Roberts JM, Koff A, Polyak K, Firpo E, Collins S, Ohtsubo M, Massagué J: Cyclins, cdks, and cyclin kinase inhibitors. Cold Spring Harbor Symp Quant Biol 1994;59:31-38.
45. Zhang H, Hannon GJ, Beach D: p21-containing cyclin kinases exist in both active and inactive states. Gene Dev 1994;8:1750-1758.
46. Kip1. Kidney Int 1999;56:1262-1265.
47. Soos TJ, Kiyokawa H, Shi Yan J, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B, Mendelsohn J, Koff A: Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Diff 1996;7:135-146.
48. Gill GN, Ill CR, Simonian MH: Angiotensin stimulation of bovine adrenocortical cell growth. Proc Natl Acad Sci USA 1977;74:5569-5573.
49. Schelling P, Ganten D, Speck G, Fischer H: Effects of angiotensin II and angiotensin II antagonist saralasin on cell growth and renin in 3T3 and SV3T3 cells. J Cell Physiol 1979;98:503-513.
50. Campbell-Boswell M, Robertson AL Jr: Effects of angiotensin II and vasopressin on human smooth muscle cell in vitro. Exp Mol Pathol 1981;35:265-276.
51. Geisterfer AAT, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988;62:749-756.
52. Berk BC, Vekshtein V, Gordon HM, Tsuda T: Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989;13:305-314.
53. Naftilan A, Pratt RE, Dzau VJ: Induction of platelet-derived growth factor A-chain and c-myc gene expression by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-1424.
54. Naftilan AJ, Pratt RE, Eldrige CS, Lin HL, Dzau VJ: Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. Hypertension 1989;13:706-711.
55. Naftilan AJ, Gilliland GK, Eldrige CS, Kraft AS: Induction of the proto-oncogene c-jun by angiotensin II. Mol Cell Biol 1990;10:5536-5540.
56. Scott-Burden T, Resink TJ, Baur U, Burgin M, Bühler FR: Amiloride sensitive activation of S6 kinase by angiotensin II in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1988;151:583-589.
57. Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992;140:95-107.
58. Bakris GL, Re RN: Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol 1993;264:F937-F942.
59. Moriyama T, Fujibayashi M, Fujiwara Y, Kaneko T, Xia C, Imai E, Kamada T, Ando A, Ueda N: Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol 1995;6:95-101.
60. Day FL, Rafty LA, Chetsreman CN, Khachigian LM: Angiotensin II (ATII)-inducible plateletderived growth factor A-chain gene expression is p42/44 extracellular signal-regulated kinase-1/2 and Egr-1 dependent and mediated via the ATII type 1 but not type 2 receptor. J Biol Chem 1999;274:23726-23733.
61. Young W, Mahboubi K, Haider A, Li I, Ferreri NR: Cyclooxygenase-2 is required for tumor necrosis factor-α and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ Res 2000;86:906-914.
62. Wolf G, Thaiss F, Schoeppe W, Stahl RAK: Angiotensin II-induced proliferation of cultured murine mesangial cells: Inhibitory role of atrial natriuretic peptide. J Am Soc Nephrol 1992;3:1270-1278.
63. Wolf G, Ziyadeh FN, Stahl RAK: Atrial natriuretic peptide stimulates the expression of transforming growth factor-β in cultured murine mesangial cells: Relationship to suppression of proliferation. J Am Soc Nephrol 1995;6:224-233.
64. Hanada S, Terada Y, Inoshita S, Sasaki S, Lohmann SM, Smolenski A, Marumo F: Overexpression of protein kinase G using adenovirus inhibits cyclin E transcription and mesangial cell cycle. Am J Physiol 2001;280:F851-F859.
65. Kohno M, Yasunari K, Minami M, Kano H, Maeda K, Mandal AK, Inoki K, Haneda S, Yoshikawa J: Regulation of rat mesangial cell migration by platelet-derived growth factor, angiotensin II, and adrenomedullin. J Am Soc Nephrol 1999;10:2495-2502.
66. Wolf G, Assmann KJM, Stahl RAK: Overexpression of aminopeptidase A abolishes the growth promoting effects of angiotensin II in cultured mouse mesangial cells. Kidney Int 1997;52:1250-1260.
67. Wolf G, Mentzel S, Assmann KJM: Aminopeptidase A: A key enzyme in the intrarenal degradation of angiotensin II. Exp Nephrol 1997;5:364-369.
68. Wolthuis A, Boes A, Rodemann HP, Grond J: Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cells. Kidney Int 1992;41:124-131.
69. Orth SR, Weinreich T, Bönisch S, Weih M, Ritz E: Angiotensin II induces hypertrophy and hyperplasia in adult human mesangial cells. Exp Nephrol 1995;3:23-33.
70. Mattana J, Singhal PC: L-Arginine supplementation antagonizes the effects of angiotensin II and endothelin 1 on mesangial cell proliferation. Cell Physiol Biochem 1995;5:176-192.
71. 1 receptors. Kidney Int 1994;45:177-184.
72. Gómez-Garre D, Ruiz-Ortega M, Ortego M, Largo R, López-Armada M, Plaza JJ, González E, Egido J: Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996;27:885-892.
73. Higueruelo S, Romero S: Angiotensin II requires PDGF-BB to induce DNA synthesis in rat mesangial cells cultured in an exogenous insulin-free medium. Nephrol Dial Transplant 1997;12:694-700.
74. Anderson PW, Do YS, Hsueh WA: Angiotensin II causes mesangial cell hypertrophy. Hypertension 1993;21:29-35.
75. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
76. Schulze-Lohoff E, Köhler M, Fees H, Reindl N, Sterzel RB: Divergent effects of arginine vasopressin and angiotensin II on proliferation and expression of the immediate early genes c-fos, c-jun and EGR-1 in cultured rat glomerular mesangial cells. J Hyperten 1993;11:127-134.
77. Huwiler A, Stabel S, Fabbro D, Pfeilschifter J: Platelet-derived growth factor and angiotensin II stimulate the mitogen-activated protein kinase cascade in renal mesangial cells: Comparison of hypertrophic and hyperplastic agonists. Biochem J 1995;305:777-784.
78. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 1992;19:464-474.
79. Mervaala E, Müller DN, Schmidt F, Park JK, Gross V, Bader M, Breu V, Ganten D, Haller H, Luft FC: Blood pressure-indepedent effects in rats with human renin and angiotensinogen genes. Hypertension 2000;35:587-594.
80. Amann K, Nichols C, Törnig J, Schwarz U, Zeier M, Mall G, Ritz E: Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996;11:1003-1011.
81. Wu LL, Yang N, Roe CJ, Cooper ME, Gilbert RE, Atkins RC, Lan HY: Macrophage and myofibroblast proliferation in remnant kidney: Role of angiotensin II. Kidney Int 1997;52(suppl 63):S221-S225.
82. Grandaliano G, Ranieri E, Monno R, Gesualdo L, Schena FP: Ramipril inhibits in vitro human mesangial cell proliferation and platelet-derived growth factor expression. Exp Nephrol 1999;7:229-235.
83. 411 in vascular smooth muscle cells. J Biol Chem 1999;274:36843-36851.
84. Bokemeyer D, Schmitz U, Kramer HJ: Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor. Kidney Int 2000;58:549-558.
85. Mondorf UF, Geiger H, Herrero M, Zeuzem S, Piiper A: Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells. FEBS Lett 2000;472:129-132.
86. Wolf G, Ziyadeh FN, Zahner G, Stahl RAK: Angiotensin II is mitogenic for cultured rat glomerular endothelial cells. Hypertension 1996;27:897-905.
87. 1) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol 2000;157:111-122.
88. Pupilli C, Lasagni L, Romagnani P, Bellini F, Mannelli M, Misciglia N, Mavilia C, Vellei U, Villari D, Serio M: Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endotheliall growth factor in human mesangial cells. J Am Soc Nephrol 1999;10:245-255.
89. Lee LK, Meyer TW, Pollock AS, Lovett DH: Endothelial cell injury initiates glomerular sclerosis in the rat remant kidney. J Clin Invest 1995;96:953-964.
90. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM: Angiotensin II induces apoptosis of human endothelial cells. Circ Res 1997;81:970-976.
91. Sharma M, Shrama R, Greene AS, McCarthy ET, Savin VJ: Documentation of angiotensin II receptors in glomerular epithelial cells. Am J Physiol 1998;274:F623-F627.
92. Wolf G, Neilson EG: Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol 1990;259:F768-F777.
93. 1-receptor. Nephrol Dial Transplant 1993;8:128-133.
94. Harris RC: Regulation of S6 kinase activity in renal proximal tubule. Am J Physiol 1992;263:F127-F134.
95. 1 receptor inhibits the effect of angiotensin II on DNA and protein synthesis of rat proximal tubular cells. Exp Nephrol 1997;5:253-262.
96. 1 ANG II-receptor. Am J Physiol 1995;268:C925-C935.
97. Wolf G, Ziyadeh FN: Renal tubular hypertrophy induced by angiotensin. Semin Nephrol 1997;17:448-454.
98. Wolf G: Regulating factors of renal tubular hypertrophy. Clin Invest 1993;71:867-870.
99. Wolf G, Neilson EG: Cellular biology of tubulointerstitial growth. Curr Top Pathol 1995;88:69-97.
100. Wolf G, Neilson EG: Angiotensin II as a renal cytokine. News Physiol Sci 1994;9:40-42.
101. Wolf G, Killen PD, Neilson EG: Intracellular signaling of transcription and secretion of type IV collagen after angiotensin II-induced cellular hypertrophy in cultured proximal tubular cells. Mol Biol Cell 1991;2:219-227.
102. Wolf G, Kuncio GS, Sun MJ, Neilson EG: Expression of homeobox genes in a proximal tubular cell line derived from adult mice. Kidney Int 1991;39:1027-1033.
103. Wolf G, Mueller E, Stahl RAK, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 1993;92:1366-1372.
104. Wolf G: Link between angiotensin II and TGF-β in the kidney. Miner Electrolyte Metab 1998;24:174-180.
105. Wolf G, Ziyadeh FN, Zahner G, Stahl RAK: Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: Attenuation after stable transfection with the c-mas oncogene. Kidney Int 1995;48:1818-1827.
106. Wolf G, Neilson EG: Effects of angiotensin II on proximal tubular cells stably transfected with the c-mas oncogene. Am J Physiol 1992;263:F931-F938.
107. Kip1. Kidney Int 1996;50:2112-2119.
108. Kip1 and induction of cellular hypertrophy in renal tubular cells depends on the generation of oxygen radicals. Kidney Int 1998;54:1923-1933.
109. Wolf G: Free radical production and angiotensin. Curr Hypertens Rep 2000;2:167-173.
110. Kip1: Role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol 2000;11:1387-1397.
111. Hannken T, Schroder R, Stahl RAK, Wolf G: Atrial natriuretic peptide attenuates ANG II-induced hypertrophy of renal tubular cells. Am J Physiol Renal Physiol 2001;281:F81-F90.
112. Kip1 expression in renal tubules in vivo: Role of reactive oxygen species. J Mol Med 2001;79:382-389.
113. Kip1 expression in diabetic BBdp rats. Diabetologia 1999;42:1425-1432.
114. 1 cells. Nephrol Dial Transplant 1995;10:1305-1312.
115. Wolf G, Ziyadeh FN, Helmchen U, Zahner G, Schroeder R, Stahl RAK: ANG II is a mitogen for a murine cell line isolated from medullary thick ascending limb of Henle's loop. Am J Physiol 1995;268:F940-F947.
116. Ruiz-Ortega M, Egido J: Angiotensin II modulates cell growth-related events and synthesis of matrix proetins in renal interstitial fibroblasts. Kidney Int 1997;52:1497-1510.
117. Aizawa T, Ishizaka N, Kurokawa K, Nagai R, Nakajima H, Taguchi JI, Ohno M: Different effects of angiotensin II and catecholamine on renal cell apoptosis and proliferation in rats. Kidney Int 2001;59:645-653.
118. Satoh M, Kashihara N, Yamasaki Y, Maruyama K, Okamoto K, Maeshima Y, Sugiyama H, Sugaya T, Murakami K, Makino H: Renal interstitial fibrosis is redcued in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2001;12:317-325.
119. Smith HW: From Fish to Philosopher. Boston, Little, Brown, 1953.
120. Gomez RA, Norwood VF: Developmental consequences of the renin-angiotensin system. Am J Kidney Dis 1995;26:409-431.
121. Guron G, Friberg P: An intact renin-angiotensin system is a prerequisite for normal renal development. J Hypertens 2000;18:123-137.
122. Niimura F, Okubo S, Fogo A, Ichikawa I: Temporal and spatial expression pattern of the angiotensinogen gene in mice and rats. Am J Physiol 1997;272:R142-R147.
123. Kakuchi J, Ichiki T, Kiyama S, Hogan BLM, Fogo A, Inagami T, Ichikawa I: Developmental expression of renal angiotensin II receptor genes in the mouse. Kidney Int 1995;47:140-147.
124. Tufro-McReddie A, Johns DW, Geary KM, Dagli H, Everett AD, Chevalier RL, Carey RM, Gomez RA: Angiotensin II type 1 receptor: Role in renal growth and gene expression during normal development. Am J Physiol 1994;266:F911-F918.
125. Kakinuma Y, Sugiyama F, Taniguchi K, Horiguchi H, Ogata T, Murakami K, Yagami K, Fukamizu A: Developmental stage-specific involvement of angiotensin in murine nephrogenesis. Pediatr Nephrol 1999;13:792-799.
126. Tufro-McReddie A, Romano LM, Harris JM, Ferder L, Gomez RA: Angiotensin II regulates nephrogenesis and renal vascular development. Am J Physiol 1995;269:F110-F115.
127. Spence SG, Allen HL, Cukierski MA, Manson JM, Robertson RT, Eydelloth RS: Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology 1995;51:367-382.
128. Esthter RE, Howard TE, Marino EM, Goddard JM, Capecchi MR, Bernstein KE: Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology and reduced male fertility. Lab Invest 1996;74:953-965.
129. Tsuchida S, Matsusaka T, Chen X, Okubo S, Niimura F, Nishimura H, Fogo A, Utsunomiya H, Inagami T, Ichikawa I: Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 1998;101:755-760.
130. Luo G, Hofmann C, Bronckers AL, Sohocki M, Bradley A, Karsenty G: BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Gene Dev 1995;9:2808-2820.
131. Kitamoto Y, Tokunaga H, Tomita K: Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis. J Clin Invest 1997;99:2351-2357.
132. Bacallao R, Fine LG: Molecular events in the organization of renal tubular epithelium: from nephrogenesis to regeneration. Am J Physiol 1989;257:F913-F924.
133. Hammerman MR: Regulation of cell survival during renal devlopment. Pediatr Nephrol 1998;12:596-602.
134. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS, Rovin BH: Renoprotection. One or many therapies? Kidney Int 2001;59:1211-1226.
135. Wolf G, Panzer U, Stahl RAK: Regulatory peptides and their antagonists in nephropathies. Curr Opin Nephrol Hypertens 2000;9:233-239.